

Clovis Oncology, Inc.
Form 8-K
June 10, 2016

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): June 9, 2016

Clovis Oncology, Inc.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction

of incorporation)

5500 Flatiron Parkway, Suite 100

001-35347
(Commission

File Number)

90-0475355
(I.R.S. Employer

Identification No.)

80301

Boulder, Colorado
(Address of principal executive
offices)

(Zip Code)

Registrant's telephone number, including area code: (303) 625-5000

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.07 Submission of Matters to a Vote of Security Holders

The Annual Meeting of Shareholders (the Annual Meeting) of Clovis Oncology, Inc. (the Company) was held on June 9, 2016. At the Annual Meeting, the shareholders of the Company voted on the following two proposals and cast their votes as described below.

Proposal One

The individuals listed below were elected at the Annual Meeting to serve a three-year term on the Company's Board of Directors.

	For	Withheld	Broker Non-Votes
Brian G. Atwood	24,452,505	474,321	7,399,419
James C. Blair, Ph.D.	24,460,673	466,153	7,399,419
Paul H. Klingenstein	24,477,190	449,636	7,399,419

Proposal Two

Proposal two was to ratify the appointment of Ernst & Young LLP as auditors of the Company for fiscal year 2016, as described in the proxy materials. This proposal was approved.

For	Against	Abstained
31,740,216	239,474	346,555

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CLOVIS ONCOLOGY, INC.

June 9, 2016

By: /s/ Patrick J. Mahaffy
Name: Patrick J. Mahaffy
Title: President and Chief Executive Officer

- 3 -